This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


NeuroVive Pharmaceutical AB

Drug Names(s): BC556, OCB-030

Description: NVP018 is a Sangamide, a new class of cyclophilin-inhibiting host-targeted antivirals. Sangamides are analogs of the naturally-occurring polyketide Sanglifehrin A, produced using Biotica’s proprietary polyketide engineering technology.

Deal Structure: Biotica and NeuroVive
In March 2013, NeuroVive announced it has completed the acquisition of a portfolio of novel cyclophilin inhibitors, technology platform assets and related intellectual property rights from Biotica. No financial details of the acquisition are being disclosed.

NeuroVive and OnCore
In September 2014, NeuroVive has signed an exclusive global outlicensing agreement with OnCore BioPharma related to the development and commercialization of NeuroVives drug candidate NVP018 for oral treatment of chronic Hepatitis B Virus (HBV) infection.

The licensing agreement provides OnCore with the exclusive global rights to develop oral formulations of NVP018 for the treatment of chronic Hepatitis B infection. The compensation to NeuroVive consists of an initial upfront payment plus a number of conditional payments based on pre-determined milestones and as well payments relating to sales targets. In addition, NeuroVive will receive incremental...See full deal structure in Biomedtracker

NVP018 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug